文献速递银屑病与炎症性皮肤病

年龄影响斑块状银屑病患者IL-17与IL-23抑制剂的药物生存率:一项回顾性多中心多国队列研究

Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-06-11

本研究纳入4178例中重度斑块状银屑病患者(4866个疗程),比较≥65岁老年与<65岁年轻患者使用IL-23或IL-17抑制剂的药物生存率。结果显示年轻患者总体药物生存率更高,差异在IL-23抑制剂中显著,IL-17抑制剂中不显著;多变量分析中老年与停药风险增加相关,抗IL-23药物与停药风险降低相关。

要点

  • ≥65岁银屑病患者生物制剂停药风险高于年轻患者。
  • 老年患者中,IL-23抑制剂的药物生存率高于IL-17抑制剂。
  • 既往使用过IL-17抑制剂增加停药概率。

核心结论

  • 老年银屑病患者生物制剂治疗停药风险高于年轻成人,尤其是使用IL-23抑制剂时。
  • 在老年患者分层分析中,IL-23抑制剂的药物生存率高于IL-17抑制剂。

研究设计与样本

  • 回顾性多中心多国队列研究,纳入成人中重度斑块状银屑病患者,按年龄分为≥65岁老年组与<65岁年轻组。
  • 共纳入4178例患者和4866个治疗疗程;老年组934例(1072个疗程),年轻组3244例(3794个疗程)。
  • 采用Kaplan-Meier估计法和比例风险Cox回归模型进行药物生存分析。

主要发现

  • 考虑所有中断原因,<65岁患者总体药物生存率高于老年患者(log-rank p < 0.006)。
  • 该差异在IL-23抑制剂治疗疗程中显著(p < 0.001),在IL-17抑制剂疗程中不显著(p = 0.2)。
  • 单变量分析中,老年与治疗中断风险增加相关(HR: 1.229, 95%CI 1.062-1.422; p < 0.006)。
  • 多变量分析中,老年与治疗中断风险增加相关(HR: 1.199, 95%CI 1.010-1.422; p = 0.0377)。
  • 调整其他变量后,抗IL-23药物与治疗中断可能性降低相关(HR: 0.520, 95%CI 0.368-0.735; p < 0.001)。

临床怎么用

  • 临床为老年银屑病患者选择生物制剂时,需考虑年龄相关的停药风险。
  • 老年患者中可优先考虑IL-23抑制剂以改善药物生存。
  • 既往使用过IL-17抑制剂的患者停药概率较高,需加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scarce data related to the drug survival of biologic agents in psoriasis patients aged ≥65 years is available. OBJECTIVES: To evaluate the drug survival of interleukin (IL)-23 or the IL-17 inhibitors approved for the treatment of moderate-to-severe psoriasis in elderly patients (aged ≥65 years), compared with younger adult patients (aged <65 years), and to identify clinical predictors that can influence the drug survival. METHODS: This retrospective multicentric cohort study included adult patients with moderate-to-severe psoriasis, dissecting two-patient subcohorts based on age: elderly versus younger adults. Kaplan-Meier estimator and proportional hazard Cox regression models were used for drug survival analysis. RESULTS: We included 4178 patients and 4866 treatment courses; 934 were elderly (1072 treatment courses), and 3244 were younger patients (3794 treatment courses). Drug survival, considering all causes of interruption, was higher in patients aged <65 years than in elderly patients overall (log-rank p < 0.006). This difference was significant for treatment courses involving IL-23 inhibitors (p < 0.001) but not for those with IL-17 inhibitors (p = 0.2). According to both uni- and multi-variable models, elder age was associated with an increased risk of treatment discontinuation (univariable analysis: HR: 1.229, 95% CI 1.062-1.422; p < 0.006; multivariable analysis: HR: 1.199, 95% CI 1.010-1.422; p = 0.0377). Anti-IL-23 agents were associated with a reduced likelihood of treatment discontinuation after adjusting for other variables (HR: 0.520, 95% CI 0.368-0.735; p < 0.001). Being previously treated with IL-17 inhibitors increased the probability of discontinuation. CONCLUSIONS: Elderly patients with psoriasis have an increased risk of biologic treatment discontinuation compared with younger adult patients, particularly, if being treated with IL-23 inhibitors. However, in stratified analyses conducted in elderly patients, IL-23 inhibitors showed higher drug survival rates than IL-17 inhibitors.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Chiricozzi A, Coscarella G, Puig L, et al. Age affects drug survival rates of interleukin (IL)-17 and IL-23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi-country, cohort study. J Eur Acad Dermatol Venereol. 2024. PMID: 38860729. doi:10.1111/jdv.20143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。